REVIEW

Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation

C-Q Zhu, W Shih, C-H Ling and M-S Tsao

Department of Pathology, University Health Network, Princess Margaret Hospital, Toronto, Ontario M5G 2C4, Canada

Correspondence to:
Correspondence to:
Dr M-S Tsao
Department of Pathology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9; Ming.tsao{at}uhn.on.ca

Characteristics of the tumour that affect and predict the survival outcome of patients with cancer are prognostic markers for cancer. In non-small cell lung carcinoma (NSCLC), stage is the main determinant of prognosis and the basis for deciding options for treatment. Patients with early-stage tumour are treated by complete surgical resection, which is curative in 40–70% of patients. That there are other factors important in determining the biology of these tumours, especially genes that have a role in metastasis, is indicated. Such factors could potentially be used to further classify patients into groups according to substages that may be treated differently. During the past decade, a large number of proteins that are putatively important in carcinogenesis and cancer biology have been studied for their prognostic value in NSCLC, but none of them have been proved to be sufficiently useful in clinical diagnosis. Several markers (epidermal growth factor receptor, human epidermal growth factor receptor 2, Ki-67, p53 and Bcl-2) have been studied exhaustively. Ki-67, p53 and Bcl-2 are suggested to be important but weak prognostic markers, by meta-analyses of the results. Cyclin E, vascular endothelial growth factor A, p16^INK4A, p27^kip1 and ß-catenin are promising candidates, but require further study in large randomised clinical trial samples by using standardised assays and scoring systems. Some issues and inconsistencies in the reported studies to date are highlighted and discussed. A guideline for a multi-phase approach for conducting future studies on prognostic immunohistochemistry markers is proposed here.

Abbreviations: ADC, adenocarcinoma; CCN, cyclin; CDK, cyclin-dependent kinase; ECM, extracellular matrix; EGFR, epidermal growth factor receptor; FHIT, fragile histidine triad; HER, human epidermal growth factor receptor; HGF, hepatocyte growth factor; hTERT, human telomerase reverse transcriptase; IHC, immunohistochemistry; MMP, matrix metalloproteinase; mRNA, messenger RNA; NSCLC, non-small cell lung carcinoma; PCNA, proliferating cell nuclear antigen; SQCC, squamous cell carcinoma; TGF-ß, transforming growth factor ß; TIMP, tissue inhibitors of metalloproteinase; VEGF, vascular endothelial growth factor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• KOSACKA, M., PIESIAK, P., POREBSKA, I., KORZENIEWSKA, A., DYLA, T., JANKOWSKA, R. (2009). Cyclin A and Cyclin E Expression in Resected Non-small Cell Lung Cancer Stage I-IIIA. In Vivo 23: 519-525 [Abstract] [Full Text]  
• Zhu, Z.-H., Sun, B.-Y., Ma, Y., Shao, J.-Y., Long, H., Zhang, X., Fu, J.-H., Zhang, L.-J., Su, X.-D., Wu, Q.-L., Ling, P., Chen, M., Xie, Z.-M., Hu, Y., Rong, T.-H. (2009). Three Immunomarker Support Vector Machines-Based Prognostic Classifiers for Stage IB Non-Small-Cell Lung Cancer. JCO 27: 1091-1099 [Abstract] [Full Text]  
• Taylor, M. D., Smith, P. W., Brix, W. K., Wick, M. R., Theodosakis, N., Swenson, B. R., Kozower, B. D., Lau, C. L., Jones, D. R. (2009). Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer.. J. Thorac. Cardiovasc. Surg. 137: 43-48 [Abstract] [Full Text]  
• Sculier, J.-P. (2009). Prognostic Factors and Implications of Positron Emission Tomography. Am Soc Clin Oncol Ed Book 2009: 469-472 [Abstract] [Full Text]  
• Jeong, S. H., Lee, H.-W., Han, J. H., Kang, S. Y., Choi, J.-H., Jung, Y. M., Choi, H., Oh, Y. T., Park, K. J., Hwang, S. C., Sheen, S. S., Oh, Y. J., Kim, J. H., Lim, H.-Y. (2008). Low Expression of Bax Predicts Poor Prognosis in Resected Non-small Cell Lung Cancer Patients with Non-squamous Histology. Jpn J Clin Oncol 38: 661-669 [Abstract] [Full Text]  
• Millar, H. J., Nemeth, J. A., McCabe, F. L., Pikounis, B., Wickstrom, E. (2008). Circulating Human Interleukin-8 as an Indicator of Cancer Progression in a Nude Rat Orthotopic Human Non-Small Cell Lung Carcinoma Model. Cancer Epidemiol. Biomarkers Prev. 17: 2180-2187 [Abstract] [Full Text]  
• Yeung, J, Chang, H (2008). Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. J. Clin. Pathol. 61: 832-836 [Abstract] [Full Text]  
• Lau, S. K., Boutros, P. C., Pintilie, M., Blackhall, F. H., Zhu, C.-Q., Strumpf, D., Johnston, M. R., Darling, G., Keshavjee, S., Waddell, T. K., Liu, N., Lau, D., Penn, L. Z., Shepherd, F. A., Jurisica, I., Der, S. D., Tsao, M.-S. (2007). Three-Gene Prognostic Classifier for Early-Stage Non Small-Cell Lung Cancer. JCO 25: 5562-5569 [Abstract] [Full Text]  
• Tsao, M.-S., Aviel-Ronen, S., Ding, K., Lau, D., Liu, N., Sakurada, A., Whitehead, M., Zhu, C.-Q., Livingston, R., Johnson, D. H., Rigas, J., Seymour, L., Winton, T., Shepherd, F. A. (2007). Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non Small-Cell Lung Cancer. JCO 25: 5240-5247 [Abstract] [Full Text]  
• Barlesi, F., Giaccone, G., Gallegos-Ruiz, M. I., Loundou, A., Span, S. W., Lefesvre, P., Kruyt, F. A.E., Rodriguez, J. A. (2007). Global Histone Modifications Predict Prognosis of Resected Non Small-Cell Lung Cancer. JCO 25: 4358-4364 [Abstract] [Full Text]